Hayrettin Tumani

List of Publications by Year
in descending order

174	11,101	25034	34986
papers	citations	57 h-index	98 g-index

187	187	187	11781
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Fat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 298-302.	1.9	12
2	Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology. International Journal of Molecular Sciences, 2022, 23, 1664.	4.1	11
3	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. Annals of Neurology, 2022, 91, 192-202.	5.3	17
4	A one-year longitudinal evaluation of cerebrospinal fluid and blood neurochemical markers in a patient with cryptococcal meningitis complicated by ischemic stroke.. Journal of the Neurological Sciences, 2022, 432, 120090.	0.6	3
5	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. Journal of Neuroinflammation, 2022, 19, 19.	7.2	82
6	Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nature Reviews Neurology, 2022, 18, 158-172.	10.1	205
7	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
8	The Sexual Dimorphism in Cerebrospinal Fluid Protein Content Does Not Affect Intrathecal IgG Synthesis in Multiple Sclerosis. Journal of Personalized Medicine, 2022, 12, 977.	2.5	1
9	Guillainâ€“BarrÃ© syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. Journal of Neurology, 2021, 268, 1133-1170.	3.6	286
10	Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110225.	3.5	1
11	Ongoing challenges in unravelling the association between COVID-19 and Guillain-BarrÃ© syndrome. Brain, 2021, 144, e44-e44.	7.6	6
12	Automated Analysis of Cerebrospinal Fluid Cells Using Commercially Available Blood Cell Analysis Devicesâ€”A Critical Appraisal. Cells, 2021, 10, 1232.	4.1	8
13	Different Inflammatory Signatures in Alzheimerâ€™s Disease and Frontotemporal Dementia Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2021, 81, 629-640.	2.6	18
14	Diagnostic biomarkers in tear fluid: from sampling to preanalytical processing. Scientific Reports, 2021, 11, 10064.	3.3	32
15	Associations between multiple sclerosis and incidence of heart diseases: Systematic review and meta-analysis of observational studies. Multiple Sclerosis and Related Disorders, 2021, 56, 103279.	2.0	10
16	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	38
17	CSF Findings in Acute NMDAR and LGI1 Antibodyâ€“Associated Autoimmune Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	24
18	Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway. Annals of Clinical and Translational Neurology, 2021, 8, 2228-2234.	3.7	4

#	Article	IF	Citations
19	VaricellaÂzoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study. Journal of Neurology, 2021, , 1.	3.6	10
20	The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis. Cells, 2021, 10, 3056.	4.1	17
21	CSF and blood Kallikrein-8: a promising early biomarker for Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 40-48.	1.9	16
22	Tick-Borne Encephalitis: A Differential Pattern of Intrathecal Humoral Immune Response and Inflammatory Cell Composition Compared with Other Viral CNS Infections. Cells, 2020, 9, 2169.	4.1	3
23	Serum neurofilament light chain. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	25
24	Genetic determinants of the humoral immune response in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e827.	6.0	7
25	Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis. Cells, 2020, 9, 2543.	4.1	8
26	Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies. Biomedicines, 2020, 8, 312.	3.2	16
27	Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases. Journal of Clinical Medicine, 2020, 9, 2874.	2.4	11
28	Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers and cognitive performance. Proceedings of the Nutrition Society, 2020, 79, .	1.0	1
29	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 2020, 56, 102807.	6.1	67
30	Is APOE Îµ4 associated with cognitive performance in early MS?. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e728.	6.0	11
31	Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report. BMC Neurology, 2020, 20, 227.	1.8	6
32	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 605-611.	1.9	17
33	Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies. Journal of Clinical Medicine, 2020, 9, 2025.	2.4	22
34	Drug-induced liver injury associated with the biosimilar glatiramer acetate (CliftÂ®). Multiple Sclerosis and Related Disorders, 2020, 40, 101948.	2.0	4
35	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology, 2020, 94, e407-e418.	1.1	36
36	S1 guidelines â€œlumbar puncture and cerebrospinal fluid analysisâ€•(abridged and translated version). Neurological Research and Practice, 2020, 2, 8.	2.0	23

#	Article	IF	Citations
37	The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation. Cells, 2020, 9, 842.	4.1	25
38	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. Pain, 2020, 161, 787-796.	4.2	29
39	Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis. Clinica Chimica Acta, 2019, 498, 148-153.	1.1	7
40	ElecsysÂ® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	1.9	60
41	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. JAMA Neurology, 2019, 76, 841.	9.0	48
42	CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort. Frontiers in Immunology, 2019, 10, 641.	4.8	34
43	Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?. Frontiers in Neurology, 2019, 10, 280.	2.4	87
44	Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. Frontiers in Neurology, 2019, 10, 1179.	2.4	18
45	Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial. EClinicalMedicine, 2019, 16, 98-106.	7.1	31
46	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 157-164.	1.9	174
47	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). Journal of Neurology, 2019, 266, 386-397.	3.6	24
48	Comprehensive micro<scp>RNA</scp> expression profiling in cerebrospinal fluid distinguishes between neurological disease classes. Neuropathology and Applied Neurobiology, 2019, 45, 318-323.	3.2	1
49	Intrathecal immunoglobulin M production: A promising highâ€risk marker in clinically isolated syndrome patients. Annals of Neurology, 2018, 83, 1032-1036.	5.3	23
50	The cerebrospinal fluid and barriers â€“ anatomic and physiologic considerations. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 21-32.	1.8	127
51	Epilepsy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 259-266.	1.8	7
52	MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. Journal of Neuroinflammation, 2018, 15, 88.	7.2	52
53	Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e446.	6.0	54
54	Oxidative stress in drug-naÃ¯ve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 129-143.	3.2	45

#	Article	IF	Citations
55	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89
56	Serum GFAP as a biomarker for disease severity in multiple sclerosis. Scientific Reports, 2018, 8, 14798.	3.3	164
57	Apheresis therapies for NMOSD attacks. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e504.	6.0	173
58	Erweiterte Liquor- und Blutanalyse. , 2018, , 123-134.		0
59	Gain-of-function STAT1 mutations are associated with intracranial aneurysms. Clinical Immunology, 2017, 178, 79-85.	3.2	19
60	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 639-647.	1.9	123
61	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	2.4	197
62	Intrathecal immunoglobulin synthesis in patients with symptomatic epilepsy and epilepsy of unknown etiology (â€˜cryptogenicâ€™). European Journal of Neurology, 2017, 24, 1188-1190.	3.3	7
63	GFAP in early multiple sclerosis: A biomarker for inflammation. Neuroscience Letters, 2017, 657, 166-170.	2.1	45
64	Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. Alzheimer's Research and Therapy, 2017, 9, 17.	6.2	30
65	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1092-1103.	3.0	60
66	Primary Progressive Multiple Sclerosis: Putting Together the Puzzle. Frontiers in Neurology, 2017, 8, 234.	2.4	36
67	CSF profile in primary progressive multiple sclerosis: Re-exploring the basics. PLoS ONE, 2017, 12, e0182647.	2.5	32
68	Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. Journal of Neuroinflammation, 2017, 14, 172.	7.2	16
69	Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay. High-Throughput, 2017, 6, 18.	4.4	8
70	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-311387.	1.9	207
71	6â€sulpho LacNAc⁺ dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system. Neuropathology and Applied Neurobiology, 2016, 42, 394-398.	3.2	4
72	Cognitive Reserve in Alzheimerâ€™s Dementia: Diagnostic Accuracy of a Testing-the-Limits Paradigm. Journal of Alzheimer's Disease, 2016, 52, 519-528.	2.6	2

#	Article	IF	Citations
73	Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis. Journal of Neurology, 2016, 263, 954-960.	3.6	13
74	Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. Drug Safety, 2016, 39, 1163-1174.	3.2	35
75	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a Germanâ€“Austrian retrospective multicenter study in patients with a clinically isolated syndrome. Journal of Neurology, 2016, 263, 2499-2504.	3.6	46
76	Validation of a multiplexing technique to determine the intrathecal, polyspecific antiviral immune response in multiple sclerosis. Expert Review of Molecular Diagnostics, 2016, 16, 1353-1356.	3.1	2
77	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Science Advances, 2016, 2, e1501678.	10.3	133
78	Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1Î². BMC Neurology, 2016, 16, 185.	1.8	64
79	Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7864-7869.	7.1	145
80	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Annals of Neurology, 2016, 79, 206-216.	5.3	315
81	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. Journal of Neural Transmission, 2016, 123, 289-296.	2.8	26
82	Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1202-1214.	3.0	40
83	Retinal involvement in amyotrophic lateral sclerosis: a study with optical coherence tomography and diffusion tensor imaging. Journal of Neural Transmission, 2016, 123, 281-287.	2.8	39
84	Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study. Multiple Sclerosis Journal, 2016, 22, 502-510.	3.0	87
85	The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis. Fluids and Barriers of the CNS, 2015, 12, 12.	5.0	50
86	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. Genetic Epidemiology, 2015, 39, 601-608.	1.3	15
87	Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?. International Journal of Molecular Sciences, 2015, 16, 17565-17588.	4.1	20
88	Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosisâ€”Report of Two Cases. International Journal of Molecular Sciences, 2015, 16, 14669-14676.	4.1	69
89	A Coding Variant of ANO10, Affecting Volume Regulation of Macrophages, Is Associated with Borrelia Seropositivity. Molecular Medicine, 2015, 21, 26-37.	4.4	49
90	Periventricular white matter lesion and incomplete MRZ reaction in a male patient with anti-N-methyl-D-aspartate receptor encephalitis presenting with dysphoric mania. BMJ Case Reports, 2015, 2015, bcr2014209075-bcr2014209075.	0.5	7

#	Article	IF	Citations
91	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
92	Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands. Electrophoresis, 2015, 36, 355-362.	2.4	11
93	Lipidâ€specific immunoglobulin <scp>M</scp> bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Annals of Neurology, 2015, 77, 447-457.	5.3	48
94	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	7.6	147
95	Effect of epileptic seizures on the cerebrospinal fluid â€“ A systematic retrospective analysis. Epilepsy Research, 2015, 114, 23-31.	1.6	47
96	The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's and Dementia, 2015, 11, 1407-1416.	0.8	152
97	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Multiple Sclerosis Journal, 2015, 21, 1036-1044.	3.0	78
98	Marker des Liquor cerebrospinalis und des Blutes im Äœberblick. , 2015, , 123-135.		0
99	Communicating Hydrocephalus Following Eosinophilic Meningitis Is Pathogenic for Chronic Viliuisk Encephalomyelitis in Northeastern Siberia. PLoS ONE, 2014, 9, e84670.	2.5	8
100	Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis. PLoS ONE, 2014, 9, e88680.	2.5	75
101	Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. Brain, 2014, 137, 2703-2714.	7.6	69
102	Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 344-350.	1.7	62
103	Accumulation and therapeutic modulation of 6-sulfo LacNAc ⁺ dendritic cells in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e33.	6.0	28
104	The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nature Reviews Neurology, 2013, 9, 267-276.	10.1	181
105	Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain, 2013, 136, 1048-1066.	7.6	100
106	Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Multiple Sclerosis Journal, 2013, 19, 1209-1212.	3.0	69
107	Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2073-2086.	2.3	37
108	Biochemical Markers of Autoimmune Diseases of the Nervous System. Current Pharmaceutical Design, 2012, 18, 4556-4563.	1.9	13

#	Article	IF	Citations
109	Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 375-391.	3.2	39
110	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 1-10.	2.1	81
111	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of Neuroinflammation, 2012, 9, 14.	7.2	593
112	Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. Progress in Neurobiology, 2011, 95, 670-685.	5.7	47
113	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.8	354
114	Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis. PLoS ONE, 2011, 6, e23600.	2.5	36
115	Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. Journal of Neurology, 2011, 258, 1034-1041.	3.6	67
116	Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. Annals of Neurology, 2011, 70, 520-520.	5.3	53
117	Patterns of Th1/Th2 Cytokines Predict Clinical Response in Multiple Sclerosis Patients Treated with Glatiramer Acetate. European Neurology, 2011, 65, 164-169.	1.4	26
118	Cerebrospinal fluid markers of idiopathic intracranial hypertension: Is the renin-angiotensinogen system involved?. Cephalalgia, 2011, 31, 116-121.	3.9	20
119	Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. Journal of Neurology, 2010, 257, 1855-1863.	3.6	56
120	Differential pattern of brainâ€specific CSF proteins tau and amyloidâ€beta in Parkinsonian syndromes. Movement Disorders, 2010, 25, 1284-1288.	3.9	44
121	The chemokine CXCL13 in acute neuroborreliosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 929-933.	1.9	84
122	Tau-Proteins as Gender-Specific State Markers in Amnestic Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2010, 30, 93-100.	1.5	11
123	2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Review of Proteomics, 2010, 7, 29-38.	3.0	23
124	Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neuroscience Letters, 2010, 468, 23-27.	2.1	49
125	The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS). PLoS ONE, 2010, 5, e11986.	2.5	122
126	IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated Syndrome. PLoS ONE, 2009, 4, e7638.	2.5	106

#	Article	IF	Citations
127	Unsolved Medical Problems: Blood-brain barrier in neurodegenerative diseases: perspectives for Nanomedicine. European Journal of Nanomedicine, 2009, 2, .	0.6	1
128	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology, 2009, 73, 1914-1922.	1.1	653
129	Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiology of Disease, 2009, 35, 117-127.	4.4	104
130	Candidate biomarkers of chronic inflammatory demyelinating polyneuropathy (CIDP): Proteome analysis of cerebrospinal fluid. Journal of Neuroimmunology, 2009, 214, 109-112.	2.3	21
131	Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. Journal of Neuroimmunology, 2009, 217, 95-101.	2.3	35
132	CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillainâ€BarrÃ© syndrome. Muscle and Nerve, 2009, 40, 42-49.	2.2	48
133	Cerebrospinal fluid biomarkers in Guillain-BarrÃ© syndrome â€“ Where do we stand?. Journal of Neurology, 2009, 256, 3-12.	3.6	57
134	Cognitive Impairment in Superficial Siderosis of the Central Nervous System: A Case Report. Cerebellum, 2009, 8, 61-63.	2.5	8
135	EFNS guidelines on diseaseâ€specific CSF investigations. European Journal of Neurology, 2009, 16, 760.	3.3	73
136	CSF proteome analysis in clinically isolated syndrome (CIS): Candidate markers for conversion to definite multiple sclerosis. Neuroscience Letters, 2009, 452, 214-217.	2.1	57
137	CIS case studies. Journal of the Neurological Sciences, 2009, 287, S7-S10.	0.6	3
138	Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease. Journal of Alzheimer's Disease, 2009, 17, 541-551.	2.6	74
139	Immunological and histochemical analyses of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders. Acta Neuropsychiatrica, 2009, 21, 51-57.	2.1	4
140	ZNS und Nervensystem. , 2009, , 321-349.		0
141	Proteome Analysis of Cerebrospinal Fluid in Amyotrophic Lateral Sclerosis (ALS). Neurochemical Research, 2008, 33, 2358-2363.	3.3	48
142	Diagnosis of cerebral toxoplasmosis by detection of Toxoplasma gondii tachyzoites in cerebrospinal fluid. Journal of Neurology, 2008, 255, 939-941.	3.6	13
143	Biochemical Markers in CSF of ALS Patients. Current Medicinal Chemistry, 2008, 15, 1788-1801.	2.4	52
144	Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Review of Molecular Diagnostics, 2008, 8, 479-494.	3.1	77

#	Article	IF	Citations
145	Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1134-1136.	1.9	78
146	Identification of disease-related biomarkers by proteome analysis of cerebrospinal fluid in Guillainâ€“BarrÃ© syndrome. Future Neurology, 2007, 2, 629-631.	0.5	0
147	Cerebrospinal fluid proteome profile in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 840-849.	3.0	66
148	Proteome analysis of cerebrospinal fluid in Guillainâ€“BarrÃ© syndrome (GBS). Journal of Neuroimmunology, 2007, 185, 190-194.	2.3	40
149	Erythropoietin in Cerebrospinal Fluid: Age-related Reference Values and Relevance in Neurological Disease. Neurochemical Research, 2007, 32, 1163-1168.	3.3	22
150	Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis. Journal of Neurology, 2007, 254, II69-II72.	3.6	7
151	Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 143-148.	3.0	106
152	Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology, 2006, 66, 852-856.	1.1	236
153	The Neurofilament Heavy Chain (NfH^{SMI35}) in the Cerebrospinal Fluid Diagnosis of Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2006, 21, 291-295.	1.5	56
154	Rare indications of IVIG therapy in neurological diseases based on case reports and small studies. Journal of Neurology, 2006, 253, v66-v69.	3.6	1
155	Neurofilament heavyâ€chain NfH‹sup›SMI35‹/sup› in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Movement Disorders, 2006, 21, 2224-2227.	3.9	68
156	Isolated bloodâ€“cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. Journal of Neurology, 2005, 252, 1067-1073.	3.6	98
157	Reversible impaired memory induced by pulsed methylprednisolone in patients with MS. Neurology, 2005, 64, 1971-1973.	1.1	27
158	Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 261-265.	3.0	60
159	Prostaglandin D Synthase (Î²-trace) in Healthy Human Sleep. Sleep, 2004, 27, 867-874.	1.1	59
160	Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neuroscience Letters, 2003, 353, 57-60.	2.1	87
161	Tau protein in cerebrospinal fluid (CSF): a bloodâ€“CSF barrier related evaluation in patients with various neurological diseases. Neuroscience Letters, 2001, 300, 95-98.	2.1	91
162	Inhibition of glutamine synthetase in rabbit pneumococcal meningitis is associated with neuronal apoptosis in the dentate gyrus. , 2000, 30, 11-18.		23

#	Article	IF	Citations
163	Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. Journal of Neuroimmunology, 2000, 110, 244-251.	2.3	80
164	Glatiramer acetate (Copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neuroscience Letters, 2000, 289, 205-208.	2.1	38
165	Glutamine Synthetase in Cerebrospinal Fluid, Serum, and Brain. Archives of Neurology, 1999, 56, 1241.	4.5	64
166	Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. Epilepsy Research, 1999, 36, 75-82.	1.6	68
167	Kinetics of Serum Neuron-Specific Enolase and Prolactin in Patients After Single Epileptic Seizures. Epilepsia, 1999, 40, 713-718.	5.1	43
168	Expression of the beta-trace protein in human pachymeninx as revealed by in situ hybridization and immunocytochemistry. Journal of Neuroscience Research, 1999, 57, 730-734.	2.9	19
169	?-Trace protein in cerebrospinal fluid: A blood-CSF barrier-related evaluation in neurological diseases. Annals of Neurology, 1998, 44, 882-889.	5.3	67
170	Intercellular adhesion molecule-1 in cerebrospinal fluidâ€"the evaluation of blood-derived and brain-derived fractions in neurological diseases. Journal of Neuroimmunology, 1998, 87, 156-161.	2.3	31
171	Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. Journal of the Neurological Sciences, 1998, 155, 44-49.	0.6	42
172	Lumbar and ventricular CSF protein, leukocytes, and lactate in suspected bacterial CNS infections. Neurology, 1998, 51, 1710-1714.	1.1	47
173	Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldtâ€"Jakob disease. Neuroscience Letters, 1997, 225, 210-212.	2.1	332
174	Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology, 1994, 44, 1523-1523.	1.1	223